Fibromyalgia:
Practical Treatments for the Family Physician
Richard N. Podell, MD
Source: Perspectives: A View of Family Medicine in
(Written for Perspectives (4Q05), a journal of the
New Jersey Academy of Family Physicians, and reprinted with permission.)
Richard N. Podell, MD, Clinical Professor in the Department of Family Medicine at UMDNJ-Robert Wood Johnson Medical School, practices internal medicine in Springfield and Somerset, New Jersey. His website address is www.DrPodell.org. [Note: If you wish to print this article, you will probably obtain better results by using the PDF version.]
According to the Arthritis Foundation, women are seven
times more likely to develop fibromyalgia than men, but the disease can affect
individuals of any age, including children and the elderly.
What Is Fibromyalgia?
As defined by the American
College of Rheumatology (ACR) in 1990 [1], the diagnosis of Fibromyalgia (FMS)
requires: 1) one key point of history: chronic widespread pain and/or soreness
in 4 quadrants of the body and 2) one key point of physical exam: painful
tenderness at 11 or more of 18 designated anatomic sites, called tender points
(See Figure 1).
Figure 1: Anatomic Locations
of the 18 Designated Fibromyalgia Tender Points
Tender points are areas of musculo-tendinous insertion.
These sites are normally more sensitive to pressure than other sites on the
body. “Normals” feel tenderness when pressed at these points using a force of 4
Kg. When pushing with the thumb, this is roughly the force needed to make the
thumbnail blanch. Where a normal person will feel tenderness at the tender
points, fibromyalgia patients feel pain.
Fibromyalgia, by this
definition, affects some 2% of adult Americans. However, if we relax the 11 of
18 tender point requirement; diffuse, chronic fibromyalgia-like pain may affect
about 10% of U.S. adults.
Most fibromyalgia patients
have mainly sore muscles with little else wrong. However, a significant number
of patients have more complex, multi-system complaints. [2,3] These symptoms
may include:
-Chronic tension and migraine
headache
-Non-restorative sleep
-Irritable bowel syndrome
-Irritable bladder syndrome
-Chronic fatigue syndrome
-Multiple chemical
sensitivity syndrome
-Vulvodynia
-Mental concentration
problems – also called “fibro fog”
-Anxiety disorders,
depression
Current research suggests
that increased pain sensitivity in fibromyalgia is due to anatomical and
functional up-regulation of the pain signaling pathways in the spinal cord and
brain. [4,5] This neurological mechanism is called neural sensitization (think
of the volume knob on a radio turned up to very high, amplifying and distorting
the radio signal).
Fibromyalgia patients report
feeling pain at much lower levels of pressure, and at heat or cold stimulation
than do healthy normal patients. Objective evidence supports the accuracy of
these reports; i.e. they are not “making it up,” but actually feel the pain.
Functional MRI studies
provide the most dramatic support for this by showing increased regional blood flow
to areas that are normally associated with a pain response. [6,7] Both normal
patients and fibromyalgia patients show regional blood flow changes when they
report pain; fibromyalgia patients show these changes at much lower levels of
stimulus. The functional MRI results have been confirmed using other objective
markers including SPECT scan and cerebral evoked potentials. [8,9]
In addition to having a
lower pain threshold, repeated stimulation causes pain intensity to increase
more rapidly in fibromyalgia patients. Once the stimulus stops, pain in the
fibromyalgia patient fades more slowly than it does in normal patients. If one
continues to apply very mild further stimulus the pain continues to fade in
normal persons. However, with fibromyalgia patients, even very light continuing
stimuli can keep the pain going. [10] Also, control subjects become less
sensitive to painful stimuli shortly after they exercise. Fibromyalgia
patients, in contrast, become more sensitive. [11] These findings are all independent
of potential confounding factors such as co-morbid depression or disability
litigation.
Cerebrospinal fluid in
Fibromyalgia Syndrome (FMS) shows the following abnormalities [12]:
·An increased level of
substance P, a pro-inflammatory mediator
·Increased level of nerve
growth factors
·Increased level of CSF
(Cerebrospinal fluid) opiates
·Reduced CSF levels of the
neurohormone, serotonin.
Animal models have shown
local injury can induce an increased sensitivity to pain similar to
fibromyalgia. Activation of NMDA (N-methyl-D-aspartate) receptors play a central
role in these experimental models. It
has been shown that ketamine, an NMDA antagonist, can prevent neural
sensitization in these animal models.
NMDA receptors are also involved in human fibromyalgia. A single I.V.
injection of ketamine improves pain in a large proportion of
fibromyalgia patients. [13]
Taken together these studies provide objective evidence to support the
conclusion that fibromyalgia patients actually feel the pain they report, and
that abnormal neural sensitization plays a key role in FMS.
Primarily, FMS is a physical illness whose “end-organ” damage is mainly
in the central nervous system. However, psychological issues can often be
relevant not only as exacerbating factors, but as secondary effects of the
illness.
About half of all chronic fibromyalgia patients become anxious or
depressed during the course of their illness, especially those whose symptoms
are severe. Fibromyalgia sufferers are also more likely to have a prior history
of depression or anxiety than are those of controls in research studies. This
suggests that mood disorders and fibromyalgia may have some common risk factors
or vulnerabilities. However, roughly
half of fibromyalgia patients have no prior history of depression or anxiety
and do not develop mood problems during their illness. And while several anti-depressants can help
fibromyalgia pain, this improvement occurs independent of whether or not the
patient is depressed.
Our best explanation is that
fibromyalgia and disorders of mood share common risk factors but are not the
same. [14] The bottom line for clinicians:
This is a physical, not mainly a mental, illness. But, when anxiety,
depression, and/or poor coping skills co-occur with fibromyalgia, it is
important to give each the attention it deserves.
Differential Diagnosis and
Evaluation:
Diagnosing fibromyalgia
demands a number of other disease rule outs [2]:
AUTOIMMUNE DISORDERS: The
first rule outs are for autoimmune/inflammatory diseases such as polymyalgia
rheumatica, Rheumatoid Arthritis (RA), myositis and Lupus. However, it is fairly
common for a patient to have an autoimmune inflammatory disease and
fibromyalgia at the same time.
An estimated 25-40% of RA
and Lupus (SLE) patients also have fibromyalgia (non-inflammatory) pain, which
is often not recognized. This is important since the best medicines for
fibromyalgia are different from those that work best for inflammation. An
important differential point is that in fibromyalgia, while joint pain is
common, joint swelling should not occur. Morning stiffness, however, is common
in fibromyalgia.
To evaluate chronic
fibromyalgia patients for autoimmune disease, a sed rate ANA and CPK should be
obtained.
MUSCULOSKELETAL: Various musculoskeletal lesions produce widespread muscle pain through direct pressure within the CNS (a spinal disc or Chiari cerebellar tonsilar herniation). Peripheral orthopedic problems can also cause diffuse pain (osteoarthritis, poor posture, repetitive strain at work, or a short leg). If fibromyalgia is severe or worsening, consider an MRI of the brain and/or cervical spine. Always evaluate posture, factors affecting repetitive strain and an orthopedic exam.
INFECTIOUS DISEASE: The
best-documented infectious causes include Lyme disease and hepatitis B. Most
likely, a wide variety of different viral illnesses can set off a fibro-like
process. In areas with a high incidence of Lyme disease, such as New Jersey,
strongly consider a Lyme screening test.
SLEEP DISORDERS: People who
have fibromyalgia have a higher than expected rate of periodic leg movement
disorder, sleep apnea, and also a more subtle version of sleep apnea called
upper airway resistance syndrome (UARS). It is also known that disrupting slow
wave sleep in a sleep lab can create fibromyalgia-type pain after just one
night. Chronic pain in turn causes non-restorative sleep. At the very least,
the sleeping patient should be observed at home by a family member for at least
30 minutes. It is also good practice to get an overnight sleep study on
fibromyalgia patients who are chronic, severe or worsening.
PSYCHIATRIC DISORDERS: A
psychiatric and mental status exam is essential in the treatment of
fibromyalgia, since fibromyalgia, anxiety and depression are often found
together, each making the other illness worse. Many psychiatric illnesses can
mimic fibromyalgia. For example, though not extremely common, some patients’
pain disappears entirely when treated for anxiety or depression.
METABOLIC DISORDERS:
Metabolic causes should be considered in fibromyalgia, including statin
medications, low thyroid, low adrenals, and, rarely, neoplastic disease. Patients should be routinely screened for CBC,
CMP, urinalysis and TSH. Also, obtain a cortisol evaluation if blood pressure
is low or if the patient has lost weight. It is important to know that
fibromyalgia patients tend to gain weight. If weight loss has occurred look for
other causes for the symptoms.
When conducting a physical on a fibromyalgia patient, be sure to check
BP and pulse both sitting and after 5 minutes of standing. Orthostatic problems
are fairly common. Neurogenic hypotension and postural orthostatic tachycardia
are among the more treatable aspects of complex fibromyalgia. Try to avoid
tilt-table testing, as it is apt to cause a prolonged flare-up of symptoms.
Pharmacotherapy for
Fibromyalgia Pain
When it comes to
pharmacotherapy for fibromyalgia there is good news and bad news. The good news
is that we are finally starting to see double blind studies for a wide range of
drugs. The bad news is that no one class of drugs is likely to help more than a
subgroup of patients. Trial and error remains the best guide for which patients
are likely to respond to which class of medicine.
Severe or complex
fibromyalgia patients tend to be unusually sensitive to the side effects of
medication This may be another manifestation of their neural sensitivity. Among
the patients with multi-system complaints there is often increased sensitivity
to bright lights, loud noises, pungent smells, and a vulnerability to stress.
When starting drug therapy
in fibro patients:
1)
Start new medicines at one half or less of the usual low-end starting
dose
2)
Titrate slowly over days or weeks
3)
Forewarn the patient about potential side-effects and that these side
effects tend to diminish over several weeks
There are no FDA approved
drugs for fibromyalgia. However, 12 distinct drug classes now have data
supporting their use in the treatment of fibromyalgia. (See Table 1). Of these,
four classes are easily used by the family physician. These are tricylic
anti-depressants, SSRI’s, norepinephrine/serotonin reuptake inhibitors
(NSRI’s), and the GABA analogue anti-seizure drugs.
Tricyclics: Both amitriptyline
(Elavil) and cyclobenzaprine (Flexeril)–a muscle relaxant related to the
tricyclics-- have favorable double blind studies supporting their use in
fibromyalgia [15,16]. Other tricyclics, such as nortriptyline (Pamelor),
may be effective, but double-blind studies have not been done. Trazadone,
though not a tricyclic, has anecdotal support.
The degree of benefit with
tricyclics can be large, but often it is only modest. Side effects include sedation,
dry mouth, prolonged QT interval, heart arrhythmia and weight gain.
I usually start with
nortriptyline, since it’s less sedating than amitriptyline. I begin
at 10 mg qhs and work up slowly in increments of 10 mg. Benefit can be seen in
one night, but a fair trial requires several weeks.
SSRI’s: SSRI’s are worth a try but
don’t expect too much benefit for pain, despite improved mood. Fluoxetine (Prozac)
has had mixed results for fibromyalgia pain.
Arnold found benefit in a 12 week long study using flexible dosing from
10 mg to 80 mg daily. [17] Goldenberg also found fluoxetine to be better
than placebo, especially when combined with tricyclics. [18]
Norepinephrine
Serotonin Reuptake Inhibitors (NSRI): Duloxetine (Cymbalta),
high-dose venlafaxine (Effexor),
and the tricyclics are the main drugs available with both norepinephrine and
serotonin-like actions.
Duloxetine became available in late
2004. It has one good double blind study showing benefit for FMS pain. [19]
This benefit was independent of its effect as an anti-depressant. In contrast,
two open label venlafaxine studies showed no benefit for fibromyalgia pain.
I find that duloxetine
is very helpful for some patients but not at all helpful for others. Nausea is a major problem, even at low doses.
However, it does tend to fade after a week or so. Duloxetine comes in 20
mg, 30 mg and 60 mg doses (samples are 30 mg). I suggest starting with 20 mg to
30 mg daily for a week, then work up toward 60 mg. This was the dose used in
the double blind study. Several studies
of depression used 120 mg daily.
Do not open the duloxetine
capsule, as the ingredients can cause gastric irritation. Do not mix with any other NSRI, or with
SSRI’s or tricyclics–except for transitioning from one to another. There are no
strict rules for how to switch over from these drugs to duloxetine. I taper down on the old drug while
introducing duloxetine. Make sure to explain the (small) potential risk
of hyperserotonin syndrome. If a psychiatrist is involved be sure to include
him/her in the discussion.
While the manufacturer has
no recommendations for or against combining duloxetine with bupropion HCl (Wellbutrin) it is important
to know that duloxetine is metabolized through the 2D6 cytochrome
pathway. Bupropion may inhibit this pathway, in effect, raising the duloxetine
dose.
GABA-related: Gabapentin (Neurontin) while approved
for seizure disorders, is also often used for pain syndromes, including
fibromyalgia. Anecdotal reports are encouraging, although there are no double
blind studies for fibromyalgia.
Because FMS patients are
especially sensitive to side effects, I usually start with a 100 mg test dose
of gabapentin at night. I then build up to at least 300 mg qhs before
adding daytime medications. If daytime
dosing is not tolerated I slowly increase the nighttime treatment dose up to
1200 mg or so qhs. Optimal dosing for
fibromyalgia pain might be at about 900 mg tid (about 2700 mg daily) though
this is higher than the manufacturer’s recommendation of up to 1800 mg a day.
Sedation, mental cloudiness, dizziness, ataxia, double vision, and tremor often
limit dosing. Unusually, increased serum creatinine has been reported.
Pregabalin (Lyrica) has been approved
for diabetic neuropathy and should be available soon. Pregabalin has one good double blind study
showing benefit in FMS. [20] Side effects are probably similar to those of gabapentin.
Other Pain Therapies:
Aspirin and the ibuprofen class are not as good for managing fibromyalgia as they are for inflammatory disease. Corticosteroids are also not very good. If these anti-inflammatories work well, reconsider the diagnosis.
Some fibromyalgia specialists
use methadone, hydrocodone (Vicodin), fentanyl transdermal
system (Duragesic)
or other opiates while others refuse to use narcotics. Unless you have a
special interest in pain medicine, most primary care physicians should probably
not get involved with chronic opioid treatment. However, prescribing occasional
narcotics for breakthrough pain is generally acceptable.
Tramadol hydrochloride
tablets (Ultram), when effective, is the first choice among
potential opioid class treatments. Tramadol hydrochloride/acetaminophen and acetaminophen may have a synergistic
effect–as in Tramadol
hydrochloride (Ultracet). [21] However, acetaminophen
is potentially hepatotoxic. Counsel patients not to take acetaminophen
with alcohol nor when fasting (with a flu) as fasting inactivates the main
detox pathway of glucoronidation. If it is necessary to take acetaminophen
regularly, oral N-acetyl cysteine (Mucomist), a precursor of
glutathione, is available in health food stores. NAC via glutathione might protect
against acetaminophen liver problems.
Innovative Therapies:
Other drugs for fibromyalgia pain are likely
to help certain sub-groups of patients, however a pain specialist should manage
their use. These “innovative” FMS drugs
include:
Sodium oxybate (Xyrem) - a GABA-B receptor
agonist: This drug is approved for a sub-type of narcolepsy, however there are
three double blind studies which show benefit for fibromyalgia. [22,23] The
most recent report was by Jon Russell, M.D., presented in abstract at the
November, 2005 meeting of the American College of Rheumatology. This study showed that Xyrem was
substantially more effective than placebo with a P value—the likelihood that
the result could have arisen by change—being less than one chance in 500. Still
Xyrem is definitely not a cure-all. Only 34.5% of persons using Xyrem were
classified as “responders”; but this was much better than the response rate for
persons on placebo. Only 12.5% of placebo treated patients had a positive
response.
My personal experience have
truly dramatic improvement with Xyrem both for fibromyalgia pain and for
quality of sleep. And it is encouraging
is that sodium oxybate is one of only a few drugs with good data that
proves it can increasing the duration of deep stage 3-4 sleep. However,
I have also found that Xyrem is a difficult medicine to use. Initially, side effects are very common.
These often but do not always fade out after a few weeks on the drug. Many of
my patients have had to stop Xyrem because of these side effects.
I recommend that persons
interested in taking Xyrem should have an over night sleep study first. Persons with sleep apnea should probably not
be put on Xyrem at this point, since Xyrem can have respiratory depressant
effects. The ordering physician should
request that the sleep specialist specifically look for the presence of
alpha-delta sleep. (This is not always done routinely.) Anecdotal suggestions are that persons with
the alpha-delta pattern—about half of fibromyalgia patients—may be more likely
to improve from taking Xyrem.
It is important to strictly
manage and monitor the use of sodium oxybate as it is identical to the
“date-rape” street drug GHB (gamma hydroxybutyric acid). To
prevent abuse and assure physician and patient education all U.S. prescriptions
for sodium oxybate are processed through a single mail-order pharmacy.
There have been no cases of abuse reported with this program.
5HT3 (Serotonin subtype 3)
Receptor Antagonists - Odansetron (Zofran): This drug, and others in the class, can cause serious
constipation and/or ischemic colitis. Only a small minority of patients are
able to tolerate odansetron on an on-going basis. However, for those
that do, it can be worthwhile.
There are also several
double blind European studies of topisetron (not available in the U.S.)
that show clear benefit for fibromyalgia pain for a large minority of patients.
[24,25]
NMDA (N-Methyl-D-Aspartate)
Receptor Antagonists: Double blind studies show that a single infusion of the NMDA
antagonist anesthetic, ketamine, can often reduce fibromyalgia pain for
hours or even days. [26] Unfortunately, I.V. ketamine requires very
careful monitoring due to potential cardiac and psychiatric side effects. Ketamine’s street name, “Special K”,
reflects it’s high potential for abuse. We look forward to industry’s
development of safer NMDA receptor antagonist drugs.
Growth Hormone: Nearly 90% of fibromyalgia
patients fail to show the expected rise in growth hormone levels immediately after
exercise. [27] Pyridostigmine (Mestinon), a
parasympathetic/acetyl-choline enhancer, corrects the growth hormone defect
within hours [28] but there is no clinical improvement short term. However, one
very good, but as yet unpublished, study suggested that pyridostigmine improved fibromyalgia related fatigue and sleep
quality. Pain also improved, but was not
statistically significant. Growth hormone injections were also effective over a
six month time frame when given to the approximately 30% of FMS patients whose
IGF1 level is in the low or low average range. However, the degree of
improvement, while statistically significant, was relatively modest.
Pyridostigmine is contraindicated if there
is heart block or bradycardia. Side effects include abdominal cramps, increased
salivation, sweating, increased bronchial secretion, diarrhea, and
hyperacidity.
Dopamine enhancing medicines: Holman and Myers published a
double blind study using pramipexole (Mirapex) for fibromyalgia pain.
(Pramipexole’s usual use is for Parkinson’s Disease and also for Periodic Leg
Movement Disorder.) Mirapex was substantially better than placebo with 42% of
Mirapex treated patients improving by 50% or more compared with only 14% for
placebo treated patients. Critical to
their success may be that Holman and Myers started treatment at a very low
dose, 0.125 mg. They then increased the dose very slowly, so that it took
several months to reach the high doses at which statistically significant
benefit was found. Nausea was a common side-effect. Using an anti-nausea agent
such as Tigan in the early stages might potentially improve tolerance. Selegeline (also known as Deprenyl) also
increases dopamine action but in a different way. There have been anecdotal
reports of benefit for fibromalgia pain, but no double blind studies.
Other Drugs:
Tizanidine (Zanaflex) and baclofen,
usually used for multiple sclerosis muscle spasm, are occasionally useful for
fibromyalgia.
CAUTION: The Food and Drug Administration has not approved any drugs as
effective for fibromyalgia. Thus, all medicines discussed in this essay are
“off label” uses. It is perfectly legal, ethical and proper for a physician to
prescribe these for fibromyalgia, and for a patient to take them. However, we
should be aware that the studies done to date have not risen to the very high
level of proof that FDA approval demands.
The potential side effects
for all these drugs are listed in the package insert that you can obtain from
your druggist, or one can look these up in a reference book such as the
PDR. Potential drug interactions pose a
more difficult problem. Some of these are known e.g. the potential interaction
between the new norepinephrine/serotonin reuptake inhibitor, Cymbalta, and
the serotonin/SSRI class of drugs such as Prozac. However, for the most
part, interactions are not tested for systematically. So, it’s important persons taking new
combinations be especially alert for adverse symptoms and also stay in close
touch with their doctors.
Table 1: MEDICINES FOR
FIBROMYALGIA PAIN.
|
CLASS/medicine |
Evidence Level* |
|
TRICYCLICS Amitryptiline (Elavil) Cyclobenzaprine (Flexeril) |
A A |
|
SEROTONIN SUBTYPE 3 (5HT3) ANTAGONIST Tropisetron** Cyclobenzaprine (Flexeril) |
A B |
|
NMDA ANTAGONIST Ketamine I.V. Dextromethorphan |
A C |
|
GROWTH HORMONE RELATED GH injections Pyridostigmine (Mestinon) |
B B |
|
NOREPINEPHRINE/SEROTONIN
REUPTAKE INHIBITORS (NSRI) Duloxetine (Cymbalta) Milnacipran** Venflaxine (Effexor) |
B B C |
|
ANTISEIZURE/GABA agonist Pregabalin (Lyrica)** Gabapentin (Neurontin) Sodium Oxybate (Xyrem) (also known
as GHB) |
B C A |
|
OPIOID-RELATED Tramadol (Ultram) Narcotic Pain Medicines |
B C |
|
ANESTHETIC Lidocaine, I.V. |
B |
|
SEROTONIN RE-UPTAKE INHIBITORS (SSRI) |